CL2018003398A1 - Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538). - Google Patents

Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).

Info

Publication number
CL2018003398A1
CL2018003398A1 CL2018003398A CL2018003398A CL2018003398A1 CL 2018003398 A1 CL2018003398 A1 CL 2018003398A1 CL 2018003398 A CL2018003398 A CL 2018003398A CL 2018003398 A CL2018003398 A CL 2018003398A CL 2018003398 A1 CL2018003398 A1 CL 2018003398A1
Authority
CL
Chile
Prior art keywords
micro
particles
sustained release
release composition
pharmaceutical sustained
Prior art date
Application number
CL2018003398A
Other languages
English (en)
Spanish (es)
Inventor
Holger Petersen
Markus Ahlheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018003398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed filed Critical
Publication of CL2018003398A1 publication Critical patent/CL2018003398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CL2018003398A 2005-12-22 2018-11-29 Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538). CL2018003398A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
EP06119086 2006-08-17

Publications (1)

Publication Number Publication Date
CL2018003398A1 true CL2018003398A1 (es) 2019-04-26

Family

ID=37772904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003398A CL2018003398A1 (es) 2005-12-22 2018-11-29 Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).

Country Status (22)

Country Link
US (7) US20090004283A1 (cg-RX-API-DMAC7.html)
EP (3) EP2359809B1 (cg-RX-API-DMAC7.html)
JP (4) JP2009520727A (cg-RX-API-DMAC7.html)
KR (5) KR101245919B1 (cg-RX-API-DMAC7.html)
CN (1) CN103251929A (cg-RX-API-DMAC7.html)
AR (1) AR058591A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006328950B2 (cg-RX-API-DMAC7.html)
BR (2) BR122019027412B8 (cg-RX-API-DMAC7.html)
CA (1) CA2631811C (cg-RX-API-DMAC7.html)
CL (1) CL2018003398A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088560A (cg-RX-API-DMAC7.html)
ES (2) ES2492641T3 (cg-RX-API-DMAC7.html)
IL (1) IL191842A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03936A (cg-RX-API-DMAC7.html)
MA (1) MA30064B1 (cg-RX-API-DMAC7.html)
NO (1) NO20082988L (cg-RX-API-DMAC7.html)
PE (1) PE20071139A1 (cg-RX-API-DMAC7.html)
PL (2) PL1968549T3 (cg-RX-API-DMAC7.html)
PT (2) PT1968549E (cg-RX-API-DMAC7.html)
RU (1) RU2464972C2 (cg-RX-API-DMAC7.html)
TW (2) TWI469788B (cg-RX-API-DMAC7.html)
WO (1) WO2007071395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2500014T5 (pl) † 2007-06-06 2025-05-05 Debiopharm International Sa Kompozycja farmaceutyczna o powolnym uwalnianiu wytworzona z mikrocząstek
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
BRPI0907011A8 (pt) * 2008-01-30 2015-09-29 Novartis Ag formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
NZ591810A (en) * 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
CA2750003A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
EP2595604B1 (en) * 2010-07-21 2016-03-30 Allergan, Inc. Method of controlling initial drug release of sirna from sustained-release implants
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
CA2832663C (en) 2011-04-25 2016-02-09 Shandong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
DE112015005320T5 (de) * 2014-11-25 2017-08-31 Cbc Co., Ltd. Janus Nanopartikel und Verfahren zur Herstellung derselben
EP4527456A3 (en) 2015-02-03 2025-05-21 Amryt Endo, Inc. Treating acromegaly with oral octreotide
JP6165356B2 (ja) * 2015-06-26 2017-07-19 オリンパス株式会社 内視鏡システム
US12396951B2 (en) * 2016-12-27 2025-08-26 Upexmed Co. Ltd. Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
KR20220163418A (ko) * 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
CN119112804A (zh) * 2020-05-08 2024-12-13 M技术株式会社 均匀分散有生理活性物质的微球及含有其的缓释制剂
KR20220163417A (ko) 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 주제가 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE2512T1 (de) * 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
DE69719367T2 (de) * 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
JP2002511075A (ja) * 1997-06-04 2002-04-09 デビオ ルシェルシュ ファルマスティク ソシエテ アノニム 薬学的活性成分の制御放出のためのインプラント及びその製造方法
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
DE60222734T2 (de) * 2002-03-15 2008-07-17 Alrise Biosystems Gmbh Mikropartikel und Verfahren zur deren Herstellung
KR20050088288A (ko) * 2002-11-06 2005-09-05 알자 코포레이션 제어식 방출 데포 제형
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
EP2444069B1 (en) * 2003-07-23 2019-06-05 Evonik Corporation Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
PT1786400E (pt) * 2004-08-12 2009-06-19 Quest Pharmaceutical Services Composições farmacêuticas para a libertação controlada de compostos biologicamente activos

Also Published As

Publication number Publication date
CA2631811A1 (en) 2007-06-28
JP6178772B2 (ja) 2017-08-09
US20220296675A1 (en) 2022-09-22
KR101245919B1 (ko) 2013-03-20
ECSP088560A (es) 2008-07-30
US20200206306A1 (en) 2020-07-02
BRPI0620063B1 (pt) 2020-09-08
IL191842A0 (en) 2008-12-29
KR20130024987A (ko) 2013-03-08
AR058591A1 (es) 2008-02-13
JP2015044823A (ja) 2015-03-12
RU2008129626A (ru) 2010-01-27
US20250082718A1 (en) 2025-03-13
KR20140133968A (ko) 2014-11-20
US20090004283A1 (en) 2009-01-01
TW200803921A (en) 2008-01-16
BRPI0620063A2 (pt) 2011-11-01
BRPI0620063A8 (pt) 2018-05-02
PL2359809T3 (pl) 2020-01-31
EP3603623A1 (en) 2020-02-05
US20180140662A1 (en) 2018-05-24
KR20080078000A (ko) 2008-08-26
WO2007071395A1 (en) 2007-06-28
AU2006328950B2 (en) 2010-07-29
KR101458728B1 (ko) 2014-11-05
US20150037420A1 (en) 2015-02-05
CN103251929A (zh) 2013-08-21
ES2492641T3 (es) 2014-09-10
EP2359809A1 (en) 2011-08-24
KR20130024986A (ko) 2013-03-08
CA2631811C (en) 2017-06-20
RU2464972C2 (ru) 2012-10-27
TW201424747A (zh) 2014-07-01
PT2359809T (pt) 2019-11-04
JP6239851B2 (ja) 2017-11-29
JP2016216467A (ja) 2016-12-22
BRPI0620063B8 (pt) 2021-05-25
US20160120935A1 (en) 2016-05-05
KR20130024988A (ko) 2013-03-08
NO20082988L (no) 2008-08-29
IN2015DN03936A (cg-RX-API-DMAC7.html) 2015-10-02
TWI468172B (zh) 2015-01-11
EP1968549B1 (en) 2014-05-14
BR122019027412B1 (pt) 2020-12-01
TWI469788B (zh) 2015-01-21
JP2009520727A (ja) 2009-05-28
AU2006328950A1 (en) 2007-06-28
PL1968549T3 (pl) 2014-10-31
MA30064B1 (fr) 2008-12-01
EP1968549A1 (en) 2008-09-17
ES2755032T3 (es) 2020-04-21
PE20071139A1 (es) 2007-11-16
EP2359809B1 (en) 2019-08-14
BR122019027412B8 (pt) 2021-07-27
PT1968549E (pt) 2014-08-29
JP2013177406A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
CL2018003398A1 (es) Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).
ATE444748T1 (de) 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
RU2398586C3 (ru) Фармацевтическая композиция
ZA200705530B (en) Sustained release pharmaceutical formulations
NO20075628L (no) Farmasøytiske formuleringer
BRPI0511900A (pt) composições farmacêuticas
IL190499A0 (en) Sustained release small molecule drug formulation
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0608885A2 (pt) composto de isômero c de sdz-rad, composição farmacêutica, e, embalagem farmacêutica
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
EP1719409A4 (en) INSECTICIDE COMPOSITION
DK2033629T3 (da) Fast farmaceutisk sammensætning omfattende valsartan
DE602006014044D1 (de) Pedalsystem
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
BRPI0615135A2 (pt) composições de fármacos contendo matrizes de hipromelose de liberação controlada
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
EP1867699A4 (en) MEANS OF PREVENTING WEAKNESS
BRPI0614413A2 (pt) composto, e, composição farmacêutica
BRPI0614412A2 (pt) composto, e, composição farmacêutica
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
DK1784174T3 (da) Famaceutisk sammensætning omfattende gabapentin
DE112005001684A5 (de) Bremskraftverstärker
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante